Commercializing your product is the most critical point in its life cycle. Nearly half of all biopharma products that launch, will underperform, and more than 25% fail to reach even 50% of their revenue forecast. Coupled with the rising costs of bringing an asset to market and peak sales falling by almost 40% since 2010, it’s imperative to make sure your product is in the best position to meet or exceed expectations.
In the past, biopharma organizations that made significant commercialization investments in both pre-launch and post-launch activities targeted at physicians along with the expensive sales force that called upon them, were typically rewarded with noteworthy sales. Today, organizations face more competition, declining reimbursement, shorter time in the market, and a slower sales uptake. Smarter investments need to be made focusing on patients, payers, prescribers, and influencers to sustain healthy profitability so your organization can continue bringing more therapies to patients.
SVA Life Sciences helps biopharma organizations commercialize their assets and enjoy continued growth throughout the lifecycle of their products. We provide our clients with strategic commercial thinking and alignment, planning and execution of commercialization activities, and support in critical functions where resource constraints exist, so the organization can make smart investments and overcome barriers to commercial success.
From proof of concept through regulatory submission, we work with organizations to evaluate a new product’s commercial potential and opportunities in targeted markets, helping to drive decisions and put their product in an optimal position to meet and exceed expectations.
We collaborate with organizations to implement and manage a launch framework to drive and monitor the entire launch process, optimizing the launch of new therapies to get the right drug to the right patient at the right time — with a rigorous focus on early revenue gain.
Stakeholder Engagement Strategy
We help you refine your product’s position in the marketplace, build and maintain access, and ensure that the brand vision is realized throughout the life cycle to maximize value and protect market share.
Verastem was referred to SVA Consulting as a Phase 3 biopharmaceutical company with 30 employees and promising data. SVA was brought in to help Verastem Oncology with the launch planning around the operations and processes, as well as helping to plan all of Verastem’s systems, which prior to SVA, their “systems” were email and a server.Read More
Exact Sciences was referred to SVA Consulting when they were a startup medical device company. In lightning speed of 19 months, Exact Sciences grew from 36 employees to over 700, moving from developing Cologuard, their pre-screening test for colon rectal cancer, to human trials, FDA approval and then to the international marketplace.Read More
MyoKardia engaged SVA Consulting at the end of its Phase 3 program to evaluate the commercial capabilities of their financial systems. The question at hand was whether MyoKardia should take on the implementation of a new ERP system, or whether their current ERP system would support a commercial company.Read More